Cerebrospinal fluid compartmental pharmacokinetics of amikacin in neonates

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 6, 2008, Pages 1934-1939

  Allegaert, K ^a   Scheers, I ^b   Adams, E ^b   Brajanoski, G ^a   Cossey, V ^a   Anderson, B J ^c  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; GLUCOSE; PROTEIN;

ANTIBIOTIC THERAPY; ARTICLE; BLOOD BRAIN BARRIER; CLINICAL ARTICLE; COMPARTMENT MODEL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG CEREBROSPINAL FLUID LEVEL; GLUCOSE BRAIN LEVEL; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKOCYTE COUNT; LUMBAR PUNCTURE; NEWBORN; NEWBORN INFECTION; PARTITION COEFFICIENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN CONTENT;

AMIKACIN; ANTI-BACTERIAL AGENTS; CEREBROSPINAL FLUID; DRUG MONITORING; HUMANS; INFANT, LOW BIRTH WEIGHT; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; INFLAMMATION; MENINGITIS, BACTERIAL;

EID: 44449134947     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01099-07     Document Type: Article

References (29)

1. Allegaert, K., B. J. Anderson, V. Cossey, and N. H. Holford. 2006. Limited predictability of amikacin clearance in extreme premature neonates at birth. Br. J. Clin. Pharmacol. 61:39-48.
2. Allegaert, K., V. Cossey, J. P. Langhendries, G. Naulaers, C. Vanhole, H. Devlieger, and B. Van Overmeire. 2004. Effects of co-administration of ibuprofen-lysine on the pharmacokinetics of amikacin in preterm infants during the first days of life. Biol. Neonate 86:207-211.
3. Anderson, B. J., K. Allegaert, J. N. van den Anker, V. Cossey, and N. H. Holford. 2007. Vancomycin pharmacokinetics in preterm neonates and the prediction of adult clearance. Br. J. Clin. Pharmacol. 63:75-84.
4. Aust, G. 2001. Vestibulotoxicity and ototoxicity of gentamycin in newborns at risk. Int. Tinnitus J. 7:27-29.
5. Bonsu, B. K., and M. B. Harper. 2005. Accuracy and test characteristics of ancillary tests of cerebrospinal fluid for predicting acute bacterial meningitis in children with low white blood cell counts in cerebrospinal fluid. Acad. Emerg. Med. 12:303-309.
6. Borradori, C., C. L. Fawer, T. Buclin, and A. Calame. 1997. Risk factors of sensorineural hearing loss in preterm infants. Biol. Neonate 71:1-10.
7. Briedis, D. J., and H. G. Robson. 1978. Cerebrospinal fluid penetration of amikacin. Antimicrob. Agents Chemother. 13:1042-1043.
8. Bruckner, O., M. Trautmann, D. Kolodziejczyk, M. Alexander, and H. Collmann. 1983. Netilmicin in human CSF after parenteral administration in patients with slightly and severely impaired blood CSF barrier. J. Antimicrob. Chemother. 11:565-571.
9. de Hoog, M., J. W. Mouton, and J. N. van den Anker. 2005. New dosing strategies for antibacterial agents in the neonate. Semin. Fetal Neonatal Med. 10:185-194.
10. de Hoog, M., B. A. van Zanten, W. C. Hop, E. Overbosch, N. Weisglas-Kuperus, and J. N. van den Anker. 2003. Newborn hearing screening: tobramycin and vancomycin are not risk factors for hearing loss. J. Pediatr. 142:41-46.
11. Eisenhut, M., T. Meehan, and L. Batchelor. 2003. Cerebrospinal fluid glucose levels and sensorineural hearing loss in bacterial meningitis. Infection 31:247-250.
12. Friedland, I. R., E. Sultan, K. H. Lehr, and B. Lenfant. 1998. Concentrations of cefpirome in cerebrospinal fluid of children with bacterial meningitis after a single intravenous dose. Antimicrob. Agents Chemother. 42:199-201.
13. Gaillard, J. L., C. Silly, A. Le Masne, B. Mahut, F. Lacaille, G. Cheron, V. Abadie, P. Hubert, V. Matha, C. Coustere, and J. Fermanian. 1995. Cerebrospinal fluid penetration of amikacin in children with community-acquired bacterial meningitis. Antimicrob. Agents Chemother. 39:253-255.
14. Garges, H. P., M. A. Moody, C. M. Cotten, P. B. Smith, K. F. Tiffany, R. Lenfestey, J. S. Li, V. G. Fowler, Jr., and D. K. Benjamin, Jr. 2006. Neonatal meningitis: what is the correlation among cerebrospinal fluid cultures, blood cultures, and cerebrospinal fluid parameters? Pediatrics 117:1094-1100.
15. Goldwater, P. N. 2005. Cefotaxime and ceftriaxone cerebrospinal fluid levels during treatment of bacterial meningitis in children. Int. J. Antimicrob. Agents 26:408-411.
16. Langhendries, J. P., O. Battisti, J. M. Bertrand, A. Francois, M. Kalenga, J. Darimont, E. Scalais, and P. Wallemacq. 1998. Adaptation in neonatology of the once-daily concept of aminoglycoside administration: evaluation of a dosing chart for amikacin in an intensive care unit. Biol. Neonate 74:351-362.
17. Langhendries, J. P., O. Battisti, J. M. Bertrand, A. Francois, J. Darimont, S. Ibrahim, P. M. Tulkens, A. Bernard, J. P. Buchet, and E. Scalais. 1993. Onee-a-day administration of amikacin in neonates: assessment of nephrotoxicity and ototoxicity. Dev. Pharmacol. Ther. 20:220-230.
18. Nau, R., F. Sorgel, and H. W. Prange. 1998. Pharmacokinetic optimalisation of the treatment of bacterial central nervous system infections. Clin. Pharmacokinet. 35:223-246.
19. Nestaas, E., H. J. Bangstad, L. Sandvik, and K. O. Wathne. 2005. Aminoglycoside extended interval dosing in neonates is safe and effective: a meta-analysis. Arch. Dis. Child. Fetal Neonatal ed. 90:F294-300.
20. Scaglione, F., G. Demartini, S. Dugnani, M. M. Arcidiacono, J. P. Pintucci, and F. Fraschini. 1999. Interpretation of middle ear fluid concentrations of antibiotics: comparison between ceftibuten, cefixime, and azithromycin. Br. J. Clin. Pharmacol. 47:267-271.
21. Sheiner, L. B., and S. L. Beal. 1979. NONMEM users guide. Division of Pharmacology, University of California, San Francisco.
22. Strausbaugh, L. J., C. D. Mandaleris, and M. A. Sande. 1977. Comparison of four aminoglycoside antibiotics in the therapy of experimental Escherichia coli meningitis. J. Lab. Clin. Med. 89:692-701.
23. Tang, H. Y., E. Hutcheson, S. Neill, M. Drummond-Borg, M. Speer, and R. L. Alford. 2002. Genetic susceptibility to aminoglycoside ototoxicity: how many are at risk? Genet. Med. 4:336-345.
24. Trujillo, H., H. Salgado, A. Uribe, N. Agudelo, C. T. Zapata, E. Luisa de Vidal, and A. I. Zuluaga. 1979. Amikacin concentration in the cerebrospinal fluid of children with acute bacterial meningitis. J. Int. Med. Res. 7:45-51.
25. Volpe, J. J. 2001. Specialized studies in the neurological evaluation, p. 134-177. In Neurology of the newborn, 4th ed. W. B. Saunders Company, Philadelphia, PA.
26. Yogev, R., and W. M. Rolling. 1981. Intraventricular levels of amikacin after intravenous administration. Antimicrob. Agents Chemother. 20:583-586.
27. Yogev, R., W. E. Schultz, and S. B. Rosenman. 1981. Penetrance of nafcillin into human ventricular fluid: correlation with ventricular pleocytosis and glucose levels. Antimicrob. Agents Chemother. 19:545-548.
28. Yow, M. D. 1977. An overview of pediatric experience with amikacin. Am. J. Med. 62:954-958.
29. Zawilla, N. H., B. Li, J. Hoogmartens, and E. Adams. 2007. Improved reversed-phase liquid chromatographic method combined with pulsed electrochemical detection for the analysis of amikacin. J. Pharm. Biomed. Anal. 43:168-173.